NasdaqGS:ABCLLife Sciences
AbCellera Biologics (ABCL) Stock Could Be 45% Undervalued After Jazz Partnership
AbCellera Biologics (NasdaqGS:ABCL) has drawn fresh attention after announcing a preclinical collaboration and license agreement with Jazz Pharmaceuticals focused on next generation T cell engaging multispecific antibodies for difficult gastrointestinal cancers and solid tumors.
See our latest analysis for AbCellera Biologics.
At a share price of $5.74, AbCellera Biologics has seen momentum build recently, with a 90 day share price return of 73.41% and a 1 year total shareholder return of...